Add articles to your saved list and come back to them anytime. This recipe features in the most popular recipes of October 2025 collection. See all stories. If there was ever any doubt whether ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback